An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease

Stopped early · Phase 3

Conditions studied: Crohn's Disease

In brief

This is a multi-centre, randomised, double-blind, active treatment, parallel group induction study in subjects with moderately-to-severely active Crohn's disease. Subjects will receive one of two doses (500 milligrams once daily, 500 milligrams twice daily) of GSK1605786A for 12 weeks. The primary objective of the study is to induce clinical response (Crohn's Disease Activity Index \[CDAI\] decrease from baseline of at least 100 points) and/or remission (CDAI score less than 150) with GSK1605786A at Week 12 in subjects with active Crohn's disease to qualify subjects for enrolment into a 52 week maintenance study (CCX114157). Secondary objectives will include assessment of the safety and evaluation of the efficacy in induction of clinical response or remission. Safety will be assessed by recording of adverse events and assessment of changes in clinical laboratory parameters, vital signs and electrocardiogram. Population pharmacokinetics will evaluate the two doses of GSK1605786A. Health outcomes assessments will include changes in Inflammatory Bowel Disease Questionnaire, SF-36, EQ-5D, and Work Productivity and Activity Impairment-Crohn's Disease.

Key facts

Study ID

NCT01536418

Run by

GlaxoSmithKline

People needed

255

Starts

2011-11-11

Expected to finish

2013-10-17

Last updated by the study team

2018-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects aged 18 years or older
• Written informed consent prior to any of the screening procedures including discontinuation of prohibited medications
• Diagnosis of Crohn's disease for more than 4 months with small bowel and/or colonic involvement
• Current evidence of moderately-to-severely active disease defined by a baseline Crohn's Disease Activity Index (CDAI) score of 220 to 450, inclusive
• Confirmation of active disease by elevated CRP (greater than or equal to the upper limit of normal for the highly sensitive C-reactive protein test) or elevated levels of faecal calprotectin
• History of inadequate response and/or intolerance or adverse event leading to discontinuation of at least one of the following treatments for Crohn's disease: corticosteroids or immunosuppressants
• Stable doses of permitted concomitant medications or having previously received, but are not currently receiving, medications for Crohn's disease
• Demonstrated ability to comply with Crohn's disease symptom recording using the interactive voice response system
• Female subjects of child-bearing potential are eligible if not pregnant or nursing and committed to use of contraceptive methods with a failure rate of less than 1 percent per year

You may not qualify if…

• Known coeliac disease, those who follow a gluten-free diet to manage symptoms of suspected coeliac disease and subjects with a positive screening test for coeliac disease (elevated anti-tissue transglutaminase antibodies)
• Diagnosis of ulcerative or indeterminate colitis
• Enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period
• Bowel surgery, other than appendectomy, within 12 weeks prior to screening and/or has planned surgery or deemed likely to need surgery for Crohn's disease during the study period
• Extensive colonic resection, subtotal or total colectomy
• Presence of ileostomies, colostomies or rectal pouches
• Fixed symptomatic stenoses of small bowel or colon
• History of more than 3 small bowel resections or diagnosis of short bowel syndrome
• Chronic use of narcotics for chronic pain defined as daily use of one or more doses of narcotic containing medicaitons
• Use of prohibited medications, including enteral feeding or elemental diet, within their specified timeframes and throughout the study. Prohibited medications include the following:
• Biologic use: Use of any TNF inhibitor (such as infliximab, adalimumab or certolizumab) or natalizumab within 10 weeks prior to Randomisation
• Corticosteroid use: Use of parenteral glucocorticoids within 4 weeks prior to Screening
• Immunospressant use: Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks prior to Screening
• Intravenous antibiotic use: Use of intravenous antibiotics for Crohn's disease within 4 weeks prior to Screening
• Enteral feeding: Use of tube or enteral feeding, elemental diet within 2 weeks prior to Screening
• Rectal Treatment: Use of 5-aminosalicylates or corticosteroid enemas or suppositories within 2 weeks prior to Screening
• Leukocytapheresis or granulocytapheresis within 2 weeks prior to Screening
• Paracetamol or acetaminophen greater than 2 grams per day
• Opioid analgesics for worsening Crohn's disease pain are prohibited when used on a regular daily basis for more than 3 days
• Digoxin or related cardiac glycosides: Use within 7 days prior to Screening
• Any previous participation in a clinical study of GSK1605786A (formerly ChemoCentryx compound CCX282-B)
• Positive immunoassay for Clostridium difficile
• Known HIV infection
• Known varicella, herpes zoster, or other severe viral infection within 6 weeks of screening
• Immunization with a live vaccine within 4 weeks of Screening and throughout the study with the exception of the influenza vaccine

Where it is running

• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — La Jolla, California, United States
• GSK Investigational Site — Aurora, Colorado, United States
• GSK Investigational Site — Denver, Colorado, United States
• GSK Investigational Site — Littleton, Colorado, United States
• GSK Investigational Site — Hamden, Connecticut, United States
• GSK Investigational Site — New Haven, Connecticut, United States
• GSK Investigational Site — Washington D.C., District of Columbia, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Port Orange, Florida, United States
• GSK Investigational Site — Suwanee, Georgia, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Chevy Chase, Maryland, United States
• GSK Investigational Site — Towson, Maryland, United States
• GSK Investigational Site — Towson, Maryland, United States
• GSK Investigational Site — Boston, Massachusetts, United States
• GSK Investigational Site — Chesterfield, Michigan, United States
• GSK Investigational Site — Rochester, Minnesota, United States
• GSK Investigational Site — Lee's Summit, Missouri, United States
• GSK Investigational Site — Mexico, Missouri, United States
• GSK Investigational Site — Brooklyn, New York, United States
• GSK Investigational Site — Lake Success, New York, United States
• GSK Investigational Site — Stony Brook, New York, United States
• GSK Investigational Site — Chapel Hill, North Carolina, United States
• GSK Investigational Site — Little Rock, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.